Earlier is not always better: Optimal time to initiate adjuvant chemotherapy after surgery for ovarian cancer.

ABSTRACT:

Objective

Tumor resection followed by adjuvant chemotherapy constitutes the cornerstone of ovarian cancer (OC) treatment. This study aimed to evaluate the impact of the time to chemotherapy (TTC) after primary surgery on the survival outcomes of patients with OC.

Methods

Patients with OC at any stage who underwent primary surgery followed by adjuvant chemotherapy between 2000 and 2021 were included in the analysis. Data were obtained from the Cancer Registries of Aachen and nine hospitals in Saxony-Anhalt. Patients were stratified into three subgroups based on the timing of chemotherapy initiation: early (≤ 21 days), intermediate (22-35 days) and late (> 35-180 days). The impact of TTC on progression-free survival (PFS) and overall survival (OS) was assessed using multivaria

SUBMITTER: Meyer-Wilmes P 

PROVIDER: S-EPMC12414076 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature